Month: May 2024

Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infections Prominent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptoms Planned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue/neurologic symptoms by PCR CDC estimates CFS affects 3.3 million AmericansWASHINGTON, May 20, 2024 (GLOBE NEWSWIRE) — 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it will fund Babesia spp testing in chronic fatigue patient samples in a study to be conducted by North Carolina State College...

CAMBRIDGE, Mass., May 20, 2024 (GLOBE NEWSWIRE) — Foghorn Therapeutics Inc. (“Foghorn”) (Nasdaq: FHTX) today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share, before underwriting discounts and commissions, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 7,220,794 shares of its common stock at a price of $5.5099 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about May 22, 2024, subject to satisfaction of customary closing conditions. All of the shares of common stock in the offering are to be sold by Foghorn. Foghorn anticipates the total...

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Arun Upadhyay, PhD, Chief Scientific Officer, Head of Research & Development, Ocugen will speak at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting being held May 29-June 1, 2024 in Vancouver, Canada. “I’m very pleased to present OCU400 data among an organization dedicated to translating cell and gene therapies into safe and effective treatments to improve patients’ lives,” said Dr. Upadhyay. “OCU400 modifier gene therapy represents a breakthrough approach for the potential treatment of broader retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA)...

ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) — Aveanna Healthcare Holdings Inc. (“Aveanna”) (NASDAQ: AVAH) today announced that its management team will attend the UBS Healthcare Services Cape Cod Summit in Chatham, MA on Tuesday, June 4, 2024, and the Jefferies Global Healthcare Conference in New York on Wednesday, June 5, 2024. Management will host 1×1 investor meetings at the UBS Healthcare Services Summit on June 4, 2024. For the Jefferies Global Healthcare Conference on June 5, 2024, management will host 1×1 investor meetings as well as a fireside chat at 3:30pm Eastern Time. Interested investors and other parties may also listen to a simultaneous webcast of the fireside chat by logging onto the Investor Relations section of the Company’s website at https://ir.aveanna.com/. The online replay will be available shortly after...

SEATTLE, May 20, 2024 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present information pertaining to the Company’s sponsored studies of its assets at the Society of Nuclear Medicine & Molecular Imaging (“SNMMI”) Annual Meeting 2024, which is being held in Toronto, Canada, from June 8-11, 2024. The Company notes that results based on investigator-initiated use of its assets are also being presented. “We are greatly encouraged by the progress of our clinical and preclinical programs,” said Thijs Spoor, CEO of Perspective. “The upcoming presentations at the SNMMI meeting will showcase our activities with VMT-α-NET...

PHOENIX, May 20, 2024 (GLOBE NEWSWIRE) — Mesa Air Group, Inc. (NASDAQ: MESA) (“Mesa” or the “Company”) today reported first quarter fiscal 2024 financial and operating results. First Quarter Fiscal 2024 Update:Total operating revenues of $118.8 million Pre-tax loss of $57.0 million, net loss of $57.9 million or $(1.41) per diluted share Adjusted net loss1 of $21.8 million2 or $(0.53) per diluted share Adjusted EBITDAR1 of $6.3 million Block hours of 46,658, an approximate 5% increase over fourth quarter fiscal 2023 Paid down $39.2 million of debt during quarter with surplus CRJ asset sale proceedsDevelopments Subsequent to Quarter End:As announced in January 2024, United Airlines agreed to significantly higher block-hour rate on E-175 flying As a result of the reduction in cargo demand, Mesa and DHL mutually agreed to wind...

David McDonald will transition to the role of Vice Chairman of DataPath Board of Directors.Nicole Robinson Appointed President of DataPath Inc.Nicole RobinsonPETAH TIKVA, Israel, May 20, 2024 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that Nicole Robinson has been appointed as President of DataPath. Ms. Robinson is an international satellite industry executive with a proven record in driving growth, managing global sales and operational teams, and deploying next-generation technology for the benefit of government and defense organizations, businesses and communities globally. She has served in key roles at Comtech Telecommunications, Ursa Space Systems, SES and General Dynamics. “We are delighted...

MONACO, May 20, 2024 (GLOBE NEWSWIRE) — Scorpio Tankers Inc. (NYSE:STNG) (“Scorpio Tankers,” or the “Company”) announced today that it has received approval from majority lenders under its 2023 $1.0 Billion Credit Facility to make an unscheduled repayment on the term portion of this credit facility in June 2024 of $223.6 million. This prepayment is to be applied against the eight quarterly principal installments of the term loan falling due between the third quarter of 2024 and the second quarter of 2026. Given the lower debt service costs arising from this prepayment, the Company’s cash break even rates are expected to decrease by approximately $3,500 per day for the first year following this prepayment. This repayment will not impact the availability under the revolving portion of this credit facility,...

– In Phase 1/2 ACHIEVE Trial, DYNE-101 Demonstrated Dose Dependent 27% Mean Splicing Correction Across All Patients in the 5.4 mg/kg Cohort at 3 Months – – DYNE-101 Showed Improvement in Myotonia, Muscle Strength, and Timed Function Tests and in DM1-ACTIVc and MDHI Patient Reported Outcomes – – In Phase 1/2 DELIVER Trial, DYNE-251 Showed 3.2% Mean Unadjusted (7.6% Mean Muscle Adjusted) Dystrophin Expression at 6 Months in 10 mg/kg Cohort Administered Monthly; 10 Times Higher Level of Dystrophin Than Reported for Weekly Administered Standard of Care1– – DYNE-251 Demonstrated Trends in Functional Improvement in NSAA, Time to Rise from Floor, 10-Meter Walk/Run Time, and Stride Velocity 95th Centile at 6 Months in 10 mg/kg Cohort – – Favorable Safety Profiles for DYNE-101 and DYNE-251 with...